# RHRI — Canonical Copy Deck (for all three concepts)

Single source of truth for the redesign. Concise, human, on-brand. No fabricated
statistics. No named clinic/startup partners (soft commitments only). No PHI.

Brand: Deep Teal `#0A5F5F` · Warm Coral `#E86C5C` · Slate Blue `#4A5F7F`.
Tagline: **Rigorous Science. Real-World Impact.**

---

## Identity

- Name: Reproductive Health Research Institute (RHRI)
- Tagline: Rigorous Science. Real-World Impact.
- One-liner: An independent network that validates reproductive-health technology
  in real clinics — before it reaches patients.
- Contact: dm@rhri.bio

## Hero

- Eyebrow: Reproductive Health Research Institute
- Headline: Rigorous Science. Real-World Impact.
- Sub: We validate new reproductive-health technology in real clinics — testing
  whether it actually works at scale, holds up economically, and improves care —
  so only innovation that earns it reaches patients.
- Primary CTA: Get involved
- Secondary CTA: How we evaluate

## The problem (Why now)

The path from lab to clinic is broken. Start-ups spend scarce capital paying
clinics to trial products that often arrive dead on launch. Clinics absorb the
risk of unproven tools. Patients get inconsistent care with no clear quality
signal. The field is producing real breakthroughs — AI embryo assessment,
microfluidics, genomics — but most of it stalls before it ever reaches a patient.

Three failures, stated plainly:
1. **Misaligned incentives** — innovators expect adoption; clinics expect a
   finished, validated product. Both lose in the gap.
2. **No shared standard** — nothing independent validates a technology before
   market entry, so marketing outruns evidence.
3. **Clinics carry the risk** — good ideas die from adoption friction while
   mediocre ones survive on a sales deck.

## What RHRI is

We are not a regulator, a lab, or a consultancy. We are independent validation
infrastructure: a decentralized network of clinics where new technology is tested
under real operating conditions, against one shared standard, and the results are
published. We validate, connect, and standardize — we complement the ecosystem
rather than compete with it.

## The Four-Pillar Framework (the core idea)

Every technology is assessed on four dimensions at once. Most evaluations test
only the first. We test all four.

1. **Replicability** — Do results hold across operators, labs, and geographies?
   Intra- and inter-operator consistency, protocol clarity, quality control.
2. **Scalability** — Does it work at clinic volume and across real workforce skill
   levels? Does scale improve consistency or break it?
3. **Sustainability** — Do performance and unit economics hold as volume grows?
   Can a clinic run it without long-term strain?
4. **Patient Value** — Lower cost, better outcomes, shorter time-to-baby, wider
   access. The only measure that ultimately counts.

## How it works (process)

A clear path from prototype to practice. (Durations are typical, not guaranteed.)
1. **Review** — We assess the technology, its stage, and what validation would
   need to prove.
2. **Protocol** — We design the study, define endpoints, and match it to clinics
   in the network.
3. **Multi-site validation** — Tested across clinics, geographies, and operator
   skill levels under real conditions.
4. **Evidence** — Outcomes, economics, and operational fit measured against the
   four pillars — and published.
5. **Implementation** — SOPs, training, and rollout support for what earns it.

## Who we serve

- **Innovators** — Credible, real-world validation clinics trust. A faster, lower-
  cost path from prototype to adoption than buying trials one clinic at a time.
- **Clinics** — First access to technology that's actually been proven, with the
  protocols and support to adopt it — and far less risk.
- **Patients** — The reason the standard exists. RHRI-validated means proven to
  improve outcomes, reduce cost, or widen access in the real world.
- **Funders** — Infrastructure that makes innovation investment pay off: it grows
  the market, speeds translation, and separates signal from noise.

## Areas of innovation (four verticals)

- **Software** — AI and digital tools across the workflow: embryo assessment,
  follicle counting, decision support, predictive analytics.
- **Hardware** — Devices that add precision and consistency: robotics,
  microfluidics, imaging, cryostorage, environmental monitoring.
- **Process** — Re-engineering how care is delivered: lab workflow, routing,
  protocol integration, quality systems.
- **Biotech** — Anything needing clinical evidence: culture media, supplements,
  genetic testing (PGT), biomarkers, novel culture systems.

## Operating model

No single headquarters. Talent and partners are distributed; pilots run where
conditions are best. Independence is the product — transparent funding, diverse
governance, published methodology. Without it, validation is worthless.

## Principles

- Evidence over enthusiasm.
- Collaboration over competition.
- Impact over publications.
- Transparency by default.
- Pragmatism over perfection.

## Three-year direction

- **2026 — Foundation.** Stand up governance and the founding team. Build the
  validation protocols. Run the first studies and publish the methodology.
- **2027 — Network.** Grow the partner-clinic network. Launch membership and the
  validation registry. Reach sustainability.
- **2028 — Standard.** "RHRI-validated" becomes a recognized mark of quality.
  Influence guidelines; launch education and certification.

## Team

- **Daniel Madero** — Founder & Director. Fertility executive focused on scaling
  clinics and building operating models across the Americas and Europe. Former CEO
  of Fertilidad Integral; senior advisor to RHEA and GenPrime.
- **Cynthia Hudson** — Clinical Strategy. SVP of Clinics at TMRW Life Sciences.
  Embryologist and medical technologist, 20+ years in reproductive medicine.
  Founder of NOVA Genomics; owner of Perch Fertility, New Jersey.
- **Felicitas Azpiroz** — Research & Science. Reproductive scientist at the
  Universitat Autònoma de Barcelona (UAB), working within the Eugin Group research
  ecosystem — bridging rigorous lab science and clinically relevant questions.

(Advisory board and partner network: in formation — shown as such, never invented.)

## Closing CTA

- Headline: This is the foundation. Now we build.
- Sub: Innovator, clinic, researcher, or funder — if you want validation to mean
  something, let's talk.
- CTA: Get involved → dm@rhri.bio

## Contact form fields

First name*, Last name*, Email*, Organization, I am a… (Innovator / Clinic /
Researcher / Investor / Patient / Other)*, Message*. Submits via mailto to
dm@rhri.bio.